Decera Clinical Education Infectious Disease Podcast

In this episode, Yvonne Gilleece, MB BCh, BAO, FRCP, uses a case study to illustrate why giving people space and time to engage in HIV care on their terms is key to overcoming potential shame and stigma.She discusses how people can be very vulnerable when engaging in HIV care, and trauma-informed care can help address these vulnerabilities in a safe, respectful way. Listen as she gives her perspectives on:Trauma-informed careOvercoming stigma and shameStaying in care Presenter:Yvonne Gilleece, MB BCh, BAO, FRCPHonorary Clinical Professor and Consultant in HIV Medicine & Sexual HealthBrighton & Sussex Medical School and University Hospitals Sussex NHS Foundation TrustChair of the British HIV AssociationLead for HIV & WomenLead for HIV & HepatitisBrighton, United KingdomContent based on an online CME program supported by an educational grant from Gilead Sciences, Inc.Link to full program:https://bit.ly/3xicSeFGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, George Lau, MD, FRCP (Edin, Lond), FHKAM (Med), FHKCP, FAASLD, MBBS (HKU), and a patient discuss opportunities to optimize care for people living with hepatitis B virus (HBV), including: Consequences to poor adherence to antiviral therapyStrategies to promote medication adherence (eg, patient education, setting up routines)The role of routine monitoring to prevent complications related to HBV such as hepatocellular carcinoma Presenter: George Lau, MD, FRCP (Edin, Lond), FHKAM (Med), FHKCP, FAASLD, MBBS (HKU)Specialist in Gastroenterology & HepatologyChairman and Senior Consultant in Gastroenterology and HepatologyHumanity and Health Medical GroupHong Kong, ChinaContent based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.Link to full program: https://bit.ly/49TuZ8UGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Gregory Huhn, MD, presents a case study exploring how to optimize oral ART for a person with a long history of different ART regimens.Listen as he discusses:Reasons to consider regimen optimization in the setting of viral suppressionEvidence for INSTIs in the setting of resistanceData on when 2-drug regimens and long-acting regimens may or may not be good optionsFaculty​Gregory Huhn, MDInterim Chief, Division of Infectious DiseasesSenior Director of HIV ServicesCook County HIV Integrated ProgramsInterim Medical Director, The RMR CORE CenterProfessor, Division of Infectious DiseasesRush University Medical CenterChicago, ILFollow along with the slides. https://bit.ly/4fHmxg5Get access to all of our new podcast episodes, subscribe to the CCO Infectious Disease podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Lucas Hill, PharmD, AAHIVP, BCACP, and Bernadette Jakeman, PharmD, PhC, BCPS, AAHIVP,discuss what pharmacists need to know to provide high-quality HIV care beyond viral suppression, including treatment strategies and tips for addressing and improving patients’ quality of life.Listen as they discuss:Reasons to consider regimen optimization in the setting of viral suppressionEvidence that LA ART may reduce internalized stigma​DHHS recommendations on proviral DNA genotyping​ FacultyLucas Hill, PharmD, AAHIVP, BCACP​HIV Pharmacist Specialist​UC San Diego Owen Clinic​Assistant Clinical Professor​UC San Diego Skaggs School of Pharmacy​San Diego, CaliforniaBernadette Jakeman, PharmD, PhC, BCPS, AAHIVP​|Associate Clinical Professor​Department of Pharmacy Practice and Administrative Sciences​University of New Mexico College of Pharmacy​Albuquerque, New Mexico Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Stuart C. Gordon, MD, FACP, FACG, AGAF, FAASLD; Marlyn J. Mayo, MD; and Brenda Remo discuss strategies for optimizing PBC pruritus care in the clinic setting.Listen to their conversation on how important it is to ask patients about their pruritus, validate their symptoms and feelings, and offer treatment options framed with realistic expectations.Presenters:Stuart C. Gordon, MD, FACP, FACG, AGAF, FAASLDProfessor of MedicineWayne State University School of MedicineDirector, Division of HepatologyHenry Ford Health Detroit, MichiganMarlyn J. Mayo, MDProfessor of Internal MedicineDivision of Digestive & Liver DiseasesUniversity of Texas SouthwesternDallas, TexasBrenda RemoPerson living with PBCDownloadable slides: https://bit.ly/3LHHiufProgram: https://bit.ly/4fBLQ3lTo get access to all of our new podcast episodes, subscribe to the CCO podcast channels on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Stuart C. Gordon, MD, FACP, FACG, AGAF, FAASLD; Marlyn J. Mayo, MD; and Brenda Remo discuss the patient experience with cholestatic pruritus in PBC.Listen to their conversation on how people describe the experience of cholestatic pruritus, the extent to which pruritus negatively affects quality of life, and the importance of educating healthcare professionals on this important symptom of PBC.Presenters:Stuart C. Gordon, MD, FACP, FACG, AGAF, FAASLDProfessor of MedicineWayne State University School of MedicineDirector, Division of HepatologyHenry Ford Health Detroit, MichiganMarlyn J. Mayo, MDProfessor of Internal MedicineDivision of Digestive & Liver DiseasesUniversity of Texas SouthwesternDallas, TexasBrenda RemoPerson living with PBCDownloadable slides: https://bit.ly/3LHHiufProgram: https://bit.ly/4fBLQ3lTo get access to all of our new podcast episodes, subscribe to the CCO podcast channels on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Bradley N. Gaynes, MD, MPH, and Glenn J. Treisman, MD, PhD, discuss the importance of screening, diagnosing, and treating depression in people living with HIV. They illustrate their discussion through a patient case and provide strategies for accomplishing this, including creation of a virtual network and employment of measurement-based care.Presenters:Bradley N. Gaynes, MD, MPHRay M. Hayworth, MD and Family Distinguished ProfessorProfessor of Psychiatry and EpidemiologyDirector, Division of Global Mental HealthCo-Director, Physician Scientist Training ProgramDepartment of PsychiatryUniversity of North Carolina School of MedicineChapel Hill, North CarolinaGlenn J. Treisman, MD, PhDEugene Meyer III Professor of Psychiatry and MedicineJohns Hopkins University School of MedicineBaltimore, MarylandDownloadable slides: https://bit.ly/3YgqqSOProgram: https://bit.ly/3WB2VCOTo get access to all of our new infectious disease podcast episodes, subscribe to the CCO infectious disease podcast channel on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Cristina Mussini, MD,and William R. Short, MD, MPH, FIDSA,discuss the potential role of ART in weight change among people living with HIV.Listen to their conversation on whether ART switch can lead to weight loss after weight gain and how to counsel people living with HIV on weight loss options, including lifestyle modifications and nonpharmacologic methods.PresentersCristina Mussini, MD​Director of Infectious Diseases Clinics​Professor of Infectious Diseases​University of Modena School of Medicine​Modena, ItalyWilliam R. Short, MD, MPH, FIDSA​Associate Director of the ​HIV Clinical Trials Unit​Associate Professor of Medicine​Division of Infectious Diseases​Perelman School of Medicine​University of Pennsylvania​Philadelphia, PennsylvaniaFollow along with the slides here.https://bit.ly/3RLdrETSee the full program here.https://bit.ly/450Ql2xGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast channel on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD, uses a case study to illustrate why patients living with HIV may disengage with their care and how best to reengage them once they present at the clinic, including discussion of:The valid reasons patients have for disengaging with their HIV careWhy the return to care should be celebratedHow to support people living with HIV as they reengage in careHow to prevent future loss to follow-upPresenter:Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhDCEO, Desmond Tutu Health FoundationDirector, Desmond Tutu HIV CentreProfessor of MedicineFaculty of Health SciencesUniversity of Cape TownCape Town, South AfricaContent based on an online CME program supported by an educational grant from Gilead Sciences, Inc.Link to full program:https://bit.ly/3xicSeFGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this second podcast of our series, hear expert faculty explore the CDC recommendations for mpox protection and discuss how vaccination can lead to immunologic equity. Topics include:Should we consider mpox an STI?What strategies can be used to improve mpox vaccination and overcome the challenges of vaccine implementation?Can mpox vaccine be coadministered with other vaccines?What is the intersection between mpox and HIV?PresentersCarlos del Rio, MD Distinguished Professor of Medicine (Infectious Diseases)Emory University School of MedicineProfessor of Global Health and EpidemiologyRollins School of Public HealthAtlanta, GeorgiaAniruddha (Anu) Hazra, MDAssistant Professor of Medicine, Section of Infectious Disease and Global HealthDirector, Infectious Diseases Fellowship ProgramMedical Director, UCM Sexual Wellness ClinicUniversity of ChicagoChicago, IllinoisLearn more about the key aspects of mpox infections and prevention through vaccination in our full program,“Protection Beyond Outbreaks: Routine Mpox Vaccination for Vulnerable Populations.”Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Hear expert faculty answer common questions about the risk, impact, and recommendations for protection against mpox, including:Why is mpox relevant to clinical practice?Who is at highest risk for mpox?How is mpox transmitted, and what are the clinical manifestations and complications of mpox infections?What are current ACIP recommendations for mpox vaccination?What about pre- and postexposure vaccination?PresentersCarlos del Rio, MD Distinguished Professor of Medicine (Infectious Diseases)Emory University School of MedicineProfessor of Global Health and EpidemiologyRollins School of Public HealthAtlanta, GeorgiaAniruddha (Anu) Hazra, MDAssistant Professor of Medicine, Section of Infectious Disease and Global HealthDirector, Infectious Diseases Fellowship ProgramMedical Director, UCM Sexual Wellness ClinicUniversity of ChicagoChicago, IllinoisLearn more about thekey aspects of mpox infections and prevention through vaccination in our full program,“Protection Beyond Outbreaks: Routine Mpox Vaccination for Vulnerable Populations.”Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Roger Bedimo, MD, MS, FACP, examines patient and regimen-based PrEP barriers and discusses practical interventions to support PrEP adherence in key populations. Topics covered include:Individual and community perspectives on PrEP barriersKey barriers by principal populationsStrategies to support PrEP deliveryPrEP options for key populationsPrEP efficacy based on adherence in cisgender men and womenComparing FTC/TDF vs FTC/TAF or CAB for PrEPPrEP in pregnancy and breastfeedingDrug–drug interactions with gender-affirming hormone therapyPresenter:Roger Bedimo, MD, MS, FACPProfessor of MedicineInterim Director, Office of Global HealthUT Southwestern Medical CenterChief, Infectious Diseases SectionVA North Texas Health Care SystemDallas, TexasContent based on an online CME program supported by an independent educational grant from ViiV Healthcare.Link to full program: https://bit.ly/49x0W6DFollow along with the slides: https://bit.ly/3KmW4pNGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Roger Bedimo, MD, MS, FACP, discusses strategies to overcome health disparities to improve PrEP uptake, including:Targeting key populations that would benefit from PrEP but have low rates of uptake, such as transgender women and people who inject drugsAddressing intersectionalityOvercoming implicit biasAddressing PrEP inequity by geographic regionExpanding PrEP uptake by expanding HCPs who prescribe itImproving PrEP education for both patients and HCPsPresenter:Roger Bedimo, MD, MS, FACPProfessor of MedicineInterim Director, Office of Global HealthUT Southwestern Medical CenterChief, Infectious Diseases SectionVA North Texas Health Care SystemDallas, TexasContent based on an online CME program supported by an independent educational grant from ViiV Healthcare.Link to full program: https://bit.ly/49x0W6DFollow along with the slides: https://bit.ly/3KmW4pNGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Roger Bedimo, MD, MS, FACP, examines provider-based and structural PrEP barriers and discusses practical methods for healthcare professionals to overcome these challenges. Topics covered include:Potential provider barriers to prescribing PrEPStrategies to facilitate conversations about PrEPAddressing the gap in PrEP provider trainingStructural barriers for PrEP coverage, such as lack of insurance and complexity of billingInformed consent for minorsCDC guidelines on HIV testing and renal or lipid monitoring while on PrEPThe role of PrEP champions or PrEP navigators, such as in the SNAPS PrEP Navigation ProgramSolutions to common problems with PrEP persistence, such as use of telehealth and same-day PrEP initiationExpanding PrEP optionsPresenter:Roger Bedimo, MD, MS, FACPProfessor of MedicineInterim Director, Office of Global HealthUT Southwestern Medical CenterChief, Infectious Diseases SectionVA North Texas Health Care SystemDallas, TexasContent based on an online CME program supported by an independent educational grant from ViiV Healthcare.Link to full program: https://bit.ly/49x0W6DFollow along with the slides: https://bit.ly/3KmW4pNGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Tristan J. Barber, MA, MD, FRCP, and Roger Bedimo, MD, MS, FACP, help you decide whether and how to modify ART in virologically suppressed individuals by critically appraising whether using newer agents may improve their treatment satisfaction.Listen to their conversation about their own approaches to evaluating whether each person living with HIV is taking the best ART regimen for them, as well as ways to proactively assess challenges people may be facing with their HIV ART. PresentersTristan J. Barber, MA, MD, FRCP​Consultant in HIV Medicine​Royal Free London NHS Foundation Trust​Honorary Associate Professor​Institute for Global Health​University College London​London, United KingdomRoger Bedimo, MD, MS, FACP​Professor of Medicine​Interim Director, Office of Global Health, UT Southwestern Medical Center​Chief, Infectious Diseases Section, ​VA North Texas Health Care System​Dallas, TexasFollow along with the slides here. https://bit.ly/44N2w2QSee the full program here.https://bit.ly/450Ql2xGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jonathan Appelbaum, MD, FACP, AAHIVS, discusses the updated CDC guidance on how to monitor for HIV in people receiving PrEP, including:Rationale for why HIV monitoring differs for people receiving LA vs daily PrEPDescription of LEVI syndromeHow to transition a person from LA PrEP to HIV ART if they test positive for HIV Presenter:Jonathan Appelbaum, MD, FACP, AAHIVSLaurie L. Dozier, Jr., MD Education Director and Professor of Internal MedicineChair, Department of Clinical SciencesFlorida State University College of MedicineMedical DirectorCare Point Health and WellnessTallahassee, FloridaLink to the full program: https://bit.ly/49x0W6DLink to the slideset: https://bit.ly/4bzZothTo get access to all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jonathan Appelbaum, MD, FACP, AAHIVS, discusses the newest data supporting LA ART use in people with adherence challenges or viremia, including:The LATITUDE study, an open-label phase III study of LA CAB + RPV in people with a suboptimal response or nonadherence to oral ARTUpdates to the Ward 86 cohort, which showed 81% of patients with viral suppression on LA CAB + RPV at Week 48The CARES study, an open-label, noninferiority phase IIIb study of LA CAB + RPV in people with baseline resistance mutationsPresenter:Jonathan Appelbaum, MD, FACP, AAHIVSLaurie L. Dozier, Jr., MD Education Director and Professor of Internal MedicineChair, Department of Clinical SciencesFlorida State University College of MedicineMedical DirectorCare Point Health and WellnessTallahassee, FloridaLink to the full program:https://bit.ly/49x0W6DLink to the slideset: https://bit.ly/4bzZothTo get access to all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Angela Branche, MD, FIDSA, and Jewel Mullen, MD, MPH, MPA, FACP, address commonly asked questions about the RSV vaccine, including:Considerations for vaccine eligibilityRecommendations for pregnant personsVaccine administration based on RSV seasonalityUse of the vaccine in persons receiving immunosuppressive medicationsSafety data (eg, risk of serious adverse events)Natural immunity of RSVVaccine cost and insurance coverageFaculty:Angela Branche, MD, FIDSAAssociate Professor of MedicineDivision of Infectious DiseasesDepartment of MedicineUniversity of RochesterRochester, New YorkJewel Mullen, MD, MPH, MPA, FACPAssociate Dean for Health EquityAssociate Professor of Population Health and Internal MedicineUniversity of Texas at Austin Dell Medical SchoolAustin, TexasContent based on a CME program supported by an educational grant from GlaxoSmithKline.Follow along with a downloadable slideset at:https://bit.ly/44vCnFuLink to full program: https://bit.ly/3WvSY9ZTo get access to all of our new podcasts, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jewel Mullen, MD, MPH, MPA, FACP, discusses strategies for implementing RSV vaccines into practice, with an emphasis on:Understanding the reasoning for Advisory Committee on Immunization Practices RSV vaccine recommendations Factors that influence vaccine uptake and patient decision-makingConsiderations for patient and healthcare professional vaccine hesitancy Building vaccine confidence in both patients and healthcare professionalsUsing shared decision-making models (eg, SHARE approach)Faculty:Jewel Mullen, MD, MPH, MPA, FACPAssociate Dean for Health EquityAssociate Professor of Population Health and Internal MedicineUniversity of Texas at Austin Dell Medical SchoolAustin, TexasContent based on a CME program supported by an educational grant from GlaxoSmithKline.Follow along with a downloadable slideset at:https://bit.ly/44vCnFuLink to full program:https://bit.ly/3WvSY9ZTo get access to all of our new podcasts, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Angela Branche, MD, FIDSA, explores the burden of RSV disease in older adults, including:RSV seasonality and disease burdenSymptoms and complications of RSV infectionOlder age as a key risk factor for severe RSV disease and complications (eg, pneumonia, hospitalization)Comorbidities associated with increased risk of RSV hospitalizationRSV hospitalization rates among different racial and ethnic minority groups and socioeconomic statuses Faculty:Angela Branche, MD, FIDSAAssociate Professor of MedicineDivision of Infectious DiseasesDepartment of MedicineUniversity of RochesterRochester, New YorkContent based on a CME program supported by an educational grant from GlaxoSmithKline.Follow along with a downloadable slideset at: https://bit.ly/44vCnFuLink to full program: https://bit.ly/3WvSY9ZTo get access to all of our new podcasts, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Using common case scenarios, Robert H. Hopkins, Jr., MD, MACP, and Laura P. Hurley, MD, MPH, discuss strategies for optimizing shingles vaccine uptake, including:The pathophysiology of shingles to better understand risk and burdenCDC guidelines and ACIP shingles vaccine recommendations, including considerations for those who are immunocompromised Strategies for optimizing shingles vaccine uptake no matter the clinical settingHow to address shingles vaccine‒related adverse events Addressing insurance-related concerns Presenters:Robert H. Hopkins, Jr., MD, MACPProfessor of Internal Medicine and PediatricsChief, Division of General Internal MedicineUniversity of Arkansas for Medical SciencesSchool of MedicineLittle Rock, ArkansasLaura P. Hurley, MD, MPHGeneral Internist and Health Services ResearcherAssociate Professor of MedicineDepartment of General Internal MedicineUniversity of Colorado Anschutz Medical CampusAurora, ColoradoLink to downloadable slides:https://bit.ly/4aWn6jhLink to full program:https://bit.ly/4aWBiJ0Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Samantha Strong, PharmD, BCACP, AAHIVP, CDCES, and Nimish Patel, PharmD, PhD, AAHIVP, cover the most impactful clinical studies presented at CROI 2024, including:New data on long-acting ART, including:The CARES study of LA CAB + RPV in a sub-Saharan African population using a public health approachThe IMPAACT 2017 MOCHA study evaluating switching to LA CAB + RPV in adolescents living with HIVThe ACTG A5359 LATITUDE study of LA CAB + RPV in people with adherence challenges to oral ARTUpdated data from San Francisco’s Ward 86 Clinic using LA CAB + RPV in people without viral suppression at baselineCase series of LA CAB (± RPV) + LEN for select people living with HIV unable to take oral ART and unable to use LA CAB + RPV aloneData on HIV and STI prevention, including:The impact of Doxy-PEP guideline implementation on STIs in men who have sex with men and transgender women in San FranciscoBIC/FTC/TAF for PEPOffering PrEP following PEPPresenters:Samantha Strong, PharmD, BCACP, AAHIVP, CDCESClinical Director of PharmacyNevada Health CentersLas Vegas, NevadaNimish Patel, PharmD, PhD, AAHIVPProfessor of Clinical PharmacySkaggs School of Pharmacy & Pharmaceutical SciencesUniversity of California, San DiegoLa Jolla, CaliforniaTo access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.See the full program here: https://bit.ly/49x0W6D Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, learn how early and sustained HBV care can be enhanced by expanding the role of primary care providers in HBV management. Learn how to:Engage key stakeholders in the provision of HBV care​Provide HBV management resources to support PCPs who are doing screening​Consider specialty and primary care collaborations that empower PCPs with clear guidance on how to manage patients living with HBVPresenters:Su Wang, MD, MPH, FACPMedical DirectorCenter for Asian Health and Viral Hepatitis ProgramsCooperman Barnabas Medical CenterRWJBarnabas-Rutgers Medical GroupAssociate MemberHealth Care Policy and Aging ResearchThe Rutgers Institute for HealthSenior AdvisorGlobal Health, Hepatitis B FoundationFlorham Park, New JerseyRichard R. Andrews, MD, MPHPresident, Houston Viral Hepatitis Task ForceFormer Co-Chair, National Task Force on Hepatitis BBoard-Certified Family MedicineAddiction Medicine PhysicianHouston, TexasRuth Brogden, MPHPatient AdvocateAmy S. Tang, MDFormer Co-Chair, National Task Force on Hepatitis BDirector of Immigrant HealthNorth East Medical ServicesSan Francisco, CaliforniaLink to full program: https://bit.ly/3TuqFHILink to the slides:https://bit.ly/44hXpHuGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Gregory Huhn, MD, MPHTM, uses a case study to explore the reasons healthcare professionals and people living with HIV may want to further optimize ART in the setting of viral suppression. To determine the best outcome for this case study, Dr Huhn discusses the reasons individuals may not be satisfied with daily oral ART and examines data to suggest that, for some individuals with virologic suppression, switching to long-acting ART may address internalized HIV stigma.Finally, Dr Huhn takes a look at the optimal candidates for switching to a long-acting ART regimen and settings where proviral DNA genotyping may be considered prior to switching.Presenter:Gregory Huhn, MD, MPHTMInterim Chief, Division of Infectious DiseasesSenior Director of HIV ServicesCook County HIV Integrated ProgramsInterim Medical Director, The RMR CORE CenterProfessor, Division of Infectious DiseasesRush University Medical CenterChicago, IllinoisTo access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.See the full program here. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Maria Buti, MD, and her patient discuss opportunities to optimize care for people living with hepatitis B virus (HBV), including: Barriers to HBV screening, including patient- and provider-specific barriers (eg, lack of education, failure to disclose or discuss risk factors, perceived low risk, stigma)Applying CDC recommendations for universal HBV screening in adults Strategies to improve HBV transitions of care (eg, improved education, simplify criteria for screening and monitoring, alternative testing sites)Importance of testing close contacts for HBV after initial diagnosis and promoting HBV vaccination Presenter: Maria Buti, MDProfessor of MedicineSenior ConsultantLiver UnitHospital Universitario Valle HebronBarcelona, SpainContent based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.Link to full program:https://bit.ly/49TuZ8UGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Joseph J. Eron, Jr., MD, and Monica Gandhi, MD, MPH, discuss the key HIV studies from CROI 2024 that are influencing their clinical practice, including:New data surrounding long-acting ART, including:The CARES study of LA CAB + RPV in a Sub-Saharan African population using a public health approachThe IMPAACT 2017 MOCHA study evaluating switching to LA CAB + RPV in adolescents living with HIVThe ACTG A5359 LATITUDE study of LA CAB + RPV in people with adherence challenges to oral ARTUpdated data from San Francisco’s Ward 86 Clinic using LA CAB + RPV in people without viral suppression at baselineCase series of LA CAB (± RPV) + LEN for select people living with HIV unable to take oral ART and unable to use LA CAB + RPV aloneData on comorbidities and coinfections, including:A REPRIEVE proteomic analysis to elucidate mechanistic pathways of statin effects on plaqueThe ACTG A5371 SLIM LIVER study of semaglutide for MASLD in people living with HIVThe impact of Doxy-PEP guideline implementation on STIs in men who have sex with men and transgender women in San FranciscoPotential novel treatment options on the horizon for people living with HIV, including:Phase II data on LEN + ISL dosed orally once weeklyEarly data on other oral weekly optionsData on bNAbs in combination or with other ART agentsPresenters:Joseph J. Eron, Jr., MDProfessor of Medicine, School of MedicineHerman and Louise Smith Distinguished ProfessorChief, Division of Infectious DiseasesDirector, Clinical Core, UNC Center for AIDS ResearchAdjunct Professor of EpidemiologyGillings School of Global Public HealthUniversity of North Carolina at Chapel HillChapel Hill, North CarolinaMonica Gandhi, MD, MPHProfessor of MedicineDivision of HIV, Infectious Diseases, and Global MedicineMedical Director, Ward 86 HIV ClinicUniversity of California, San FranciscoSan Francisco, CaliforniaContent based on an online CME program supported by independent educational grants from Gilead Sciences; Merck & Co., Inc.; and ViiV Healthcare.Link to full program: https://bit.ly/4awdWJMGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Mark S. Sulkowski, MD, FIDSA, FAASLD; Tatyana Kushner, MD, MSCE; Paul Y. Kwo, MD; and patient advocate Jacki Chen, PhD, consider barriers and solutions for more expansive HBV treatment in the United States. Topics include:Patient subgroups to consider for treatment outside guideline criteriaAdverse event and cost-effectiveness considerationsIntegration of patient perspectives in wider treatmentPresenters:Mark S. Sulkowski, MD, FIDSA, FAASLDProfessor of MedicineDirector, Division of Infectious Diseases, Johns Hopkins Bayview Medical CenterJohns Hopkins University School of MedicineBaltimore, MarylandTatyana Kushner, MD, MSCEAssociate ProfessorDivision of Liver DiseasesIcahn School of Medicine at Mount SinaiNew York, New YorkPaul Y. Kwo, MDProfessor of MedicineDirector of HepatologyStanford University School of MedicinePalo Alto, CaliforniaJacki Chen, PhDPatient Advocate Link to full program: https://bit.ly/3TuqFHILink to the slides:https://bit.ly/4a60GM4Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Robert Wong, MD, MS, and a patient discuss opportunities to optimize care for people living with hepatitis B virus (HBV), including:Opportunities to improve patient education, including education for expectant mothers with HBVPotential cultural considerations that may result in delayed HBV diagnosis and care Stigma reduction with universal HBV screening and vaccinationStrategies to improve patient education (eg, online resources, advocacy groups, use of layman’s terms and diagrams, repetition)Presenter: Robert Wong, MD, MS Clinical Associate Professor Division of Gastroenterology and HepatologyStanford University School of MedicinePalo Alto, CaliforniaContent based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.Link to full program: https://bit.ly/49TuZ8UGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Listen to Roger Bedimo, MD, MS, FACP, discuss considerations for older people living with HIV, including:Polypharmacy and deprescribingThe risk of cardiovascular events with various ART regimensApproaches for managing weight gainPresenter:Roger Bedimo, MD, MS, FACPProfessor of MedicineInterim Director, Office of Global HealthUT Southwestern Medical CenterChief, Infectious Diseases SectionVA North Texas Health Care SystemDallas, TexasGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.To download the slides: https://bit.ly/49zrnZsTo view the full online program:https://bit.ly/49x0W6D Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Dr. Bedimo discusses best practices for individualized care in transgender women living with HIV, including:Providing services in a gender-affirmative care modelProactive counseling on drug-drug interactions with gender-affirming hormone therapyStrategies to reduce adverse eventsPresenter:Roger Bedimo, MD, MS, FACPProfessor of MedicineInterim Director, Office of Global HealthUT Southwestern Medical CenterChief, Infectious Diseases SectionVA North Texas Health Care SystemDallas, TexasGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.To download the slides: https://bit.ly/49zrnZsTo view the full online program:https://bit.ly/49x0W6D Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Renslow Sherer, MD, and Trinh P. Vu, PharmD, BCIDP, discuss how to optimize the use of COVID-19 antivirals and how to navigate drug-drug interactions between COVID-19 treatments and a patient’s home medications. Their discussion includes:Current COVID-19 landscapeCOVID-19 testing and vaccination recommendationsTreatment guidelines and antiviral options for nonhospitalized adults with COVID-19Resources for assessing and managing COVID-19 antiviral-related drug-drug interactionsAnswers to learners’ most pressing questionsPresenters:Renslow Sherer, MDProfessor of MedicineSection of Infectious Diseases and Global HealthUniversity of ChicagoChicago, IllinoisTrinh P. Vu, PharmD, BCIDPClinical Pharmacy Specialist in Infectious DiseasesDepartment of PharmacyEmory University Hospital MidtownAtlanta, GeorgiaSlideset: https://bit.ly/4c6kwbJDownloadable resource:https://bit.ly/49rofP6Full program: https://bit.ly/3P16TR8Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Nancy Reau, MD, discusses new data on hepatitis B virus presented at AASLD 2023, including:Current therapiesStudies 108 and 110: Factors Linked With Lack of Virologic Suppression After 8 Yr of TAF or TDFKaiser Permanente Northern California: HCC or Death With TDF vs ETV for Chronic Hepatitis BEarly vs Late Postpartum Cessation of TDF Initiated for Prevention of Vertical HBV TransmissionInvestigational functional cure strategiesB-Together: Sequential Bepirovirsen and PegIFN Added to NA Therapy for Chronic HBV InfectionMARCH Part B: VIR-3434 ± VIR-2218 ± PegIFN Added to NA Therapy for Chronic HBV InfectionREEF-IT: JNJ-3989 + NA ± JNJ-6379 With PegIFN Add-on Consolidation in Patients With HBeAg-Positive CHBHBV003: VTP-300 + Nivolumab Added to NA Therapy for Chronic HBV InfectionCVP-NASVAC: Nasally Administered Therapeutic Vaccine for Chronic HBV InfectionPresenter:Nancy Reau, MDProfessor of MedicineRichard B. Capps Chair of HepatologyChief, Section of HepatologyAssociate Director, Solid Organ TransplantationRush University Medical Center Chicago, IllinoisLink to full program: https://bit.ly/47XJlU4 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, LaRon E. Nelson, PhD, RN, FNP, FNAP, FNYAM, FAAN, discusses the role that healthcare professionals (HCPs) may be playing in their patients’ pre-exposure prophylaxis (PrEP) persistence and strategies to modify their approach to encourage persistence, from Clinical Care Options (CCO), including:Racial disparities in the PrEP care continuumConsideration that PrEP persistence may be less about relationship to the drug than the environmentExamples of HCP implicit bias regarding PrEP responsibility based on racism and sexual prejudiceImpact of HCP implicit bias on PrEP persistenceImpact of racism on clinical cognitionThe demonstrated effects of stereotype threat and the potential healthcare implicationsWays to improve clinical conversations about PrEPProviding person-centered care to encourage PrEP persistence using the Client‑Centered Care Coordination (C4™) ModelFacultyLaRon E. Nelson, PhD, RN, FNP, FNAP, FNYAM, FAANIndependence Foundation ProfessorSchool of NursingYale UniversityNew Haven, ConnecticutFollow along with the slides: https://bit.ly/497cahKLink to full program:https://bit.ly/3ZlICsLGet access to all of our new podcasts by subscribing to the CCO Infectious Disease podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Nancy Reau, MD, and her patient discuss opportunities to optimize care for people living with hepatitis B virus and hepatitis delta virus, including:The importance of patient education along the care continuumEnsuring smooth transitions of care and communication between medical teamsScreening hepatitis delta in persons with chronic hepatitis BManaging hepatitis delta, including considerations for clinical trialsPromoting patient advocacyPresenter: Nancy Reau, MDProfessor of Medicine Chief, Section of HepatologyAssociate Director, Solid Organ TransplantationRichard B. Capps Chair of HepatologyRush University Medical CenterChicago, IllinoisContent based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.Link to full program: bit.ly/3SrMuGOGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, David Saunders discusses the value of nonstigmatizing discussions between people using HIV pre-exposure prophylaxis (PrEP) and healthcare professionals, including: Encouraging accountability to individualize adherence strategies and improve persistence to PrEPReducing stigma, discrimination, and prejudice in healthcare settings to foster PrEP persistence Faculty: David SaundersPrEP User and AdvocateLink to full program:https://bit.ly/3ZlICsLTo automatically get new episodes as soon as they launch, subscribe to the CCO Infectious Disease podcast. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Sarah M. Wood, MD, MS, discusses data and recommendations for long-acting pre-exposure prophylaxis (PrEP) as a strategy to support PrEP persistence and engagement for adolescents, including: The PrEP care continuum for adolescentsSystem barriers to PrEP coverage and privacy concerns for adolescentsThe benefits and challenges of same-day PrEP initiation and real-world data to support itInterventions to support PrEP persistencePrEP options for different populations and the data to support the efficacy of long-acting cabotegravir (CAB) PrEP from HPTN 083 and HPTN 084Data and recommendations for a CAB PrEP oral lead-inData from HPTN 083 showing no interaction between feminizing hormone therapy and long-acting CAB PrEPProject LifeSkills: a culturally specific, empowerment-based, group-delivered behavioral HIV prevention intervention for young transgender womenFacultySarah M. Wood, MD, MSAssistant Professor of Pediatrics Division of Adolescent MedicinePerelman School of MedicineUniversity of Pennsylvania Children’s Hospital of PhiladelphiaPhiladelphia, PennsylvaniaFollow along with the slides: https://bit.ly/3Ha9KmtLink to full program: https://bit.ly/3ZlICsLTo automatically get new episodes as soon as they launch, subscribe to the CCO Infectious Disease podcast show. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Angela Branche, MD, discusses RSV vaccines in older adults, including: Current Advisory Committee on Immunization Practices recommendationsRisk factors associated with severe RSV disease, including RSV-related hospitalizationsApproach to stratifying risk factors (eg, age, comorbidities) in determining which adults may benefit from the RSV vaccine Ongoing research on RSV vaccines in younger adults (eg, aged 40s and 50s years) with chronic comorbidities Health disparities related to RSV vaccinesConsiderations for a risk-based approach, rather than age alone, to determine vaccine candidacy Faculty: Angela Branche, MDAssociate Professor of MedicineDivision of Infectious DiseasesDepartment of MedicineUniversity of RochesterRochester, New YorkLink to full program: https://bit.ly/3nb25xeLink to downloadable slides: https://bit.ly/3TsXym5 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Douglas Dieterich, MD, leads a panel discussion with Camilla S. Graham, MD, MPH, and Robert Wong, MD, MS, to consider advantages and barriers to universal screening for chronic HBV infection and universal HDV screening in adults with HBV in the United States. Topics include:Updated CDC recommendations for one-time universal screening for HBVAddressing patient-, provider-, and system-level barriers to universal HBV screeningBest practices for implementation of HDV screeningPresenters:Douglas Dieterich, MDDirector, Institute for Liver MedicineProfessor of MedicineDivision of Liver DiseasesMount Sinai School of MedicineNew York, New YorkCamilla S. Graham, MD, MPHCo-Director, Viral Hepatitis ClinicDivision of Infectious DiseasesBeth Israel Deaconess Medical CenterHarvard Medical SchoolBoston, MassachusettsRobert Wong, MD, MS Clinical Associate ProfessorDivision of Gastroenterology and HepatologyStanford University School of MedicinePalo Alto, CaliforniaLink to full program:https://bit.ly/3TuqFHILink to the slides: https://bit.ly/4atS42z Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Tavell L. Kindall, PhD, DNP, ARNP, FNP-BC, AACRN, AAHIVS, FAANP, and Anne Teitelman, PhD, FNP-BC, FANNP, FAAN, discuss key PrEP considerations for advanced practice providers in primary care settings, including: The importance of having PrEP navigators to help with logistics and be a point of contact for patients Where to find education and resources to familiarize yourself with PrEP and its prescribingSafety considerations and adverse events associated with PrEP optionsPrEP coverage and costHow to discontinue PrEP and the risk of resistance if someone acquires HIV while taking PrEPFacultyTavell L. Kindall, PhD, DNP, ARNP, FNP-BC, AACRN, AAHIVS, FAANPDirector, HIV Prevention and TreatmentSt. Thomas Community Health CenterNew Orleans, LouisianaAnne Teitelman, PhD, FNP-BC, FANNP, FAANAssociate Professor Emeritus of Nursing and Global Women’s HealthDepartment of Family and Community HealthSchool of NursingUniversity of PennsylvaniaProfessorThomas Jefferson UniversityCollege of NursingPhiladelphia, PennsylvaniaLink to full program: https://bit.ly/3PZGYdR Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Mark Brennan-Ing, PhD, and Nina I. Martinez discuss mental health challenges in people living with HIV and much-needed strategies to overcome these challenges to optimize engagement in HIV care, including:The increased rates of mental health disorders and substance use among people living with HIVHow mental health disorders contribute to challenges with adherence to HIV treatment and engagement in careHow social isolation and stigma can affect outcomes despite access to HIV care and ARTThe importance of mental health screenings as part of HIV careIntegrating mental health services into HIV care as a strategy to overcome mental health challenges being a barrier to carePresenter:Mark Brennan-Ing, PhDDirector of Research and EvaluationBrookdale Center for Healthy AgingHunter CollegeThe City University of New YorkNew York, New YorkNina I. MartinezPublic Health ConsultantLink to full program: https://bit.ly/3TqVnl1 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Isolde Butler, MD, MPH, a healthcare professional caring for people living with HIV, and Marissa Gonzalez, an individual living with HIV, discuss strategies to improve healthcare professionals’ competencies in delivering optimal HIV care from the start to better support patients in overcoming barriers to sustained care engagement.The topics they discuss include: An introduction to the guidelines on ART initiation—start quickly and choose the therapy that is effective and tolerableThe patient experience, from initial diagnosis to treatment selection, noting that where people get diagnosed matters in determining the level of support they will receiveThe complete HIV care team: healthcare professionals, navigators, case managers, behavioral health providers, mental health providers, and so on. Smaller clinics may not be able to provide adequate support to meet all patient needsHow to navigate the first visit after an HIV diagnosis, including patient–provider treatment discussions on the available therapies that can help with stigmaHIV stigma education; navigating the miseducation and misinformationPresenters:Isolde F. Butler, MD, MPHChief Medical OfficerCresentcareNew Orleans, LouisianaMarissa GonzalezChairCommunity Advisory BoardThe Well ProjectLink to full program:https://bit.ly/3TqVnl1 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Babafemi Taiwo, MBBS, and Vincent Crisostomo discuss the evolving treatment landscape for aging people living with HIV, encompassing the clinical and external resources necessary to support physical and psychosocial health. The topics discussed include:• Mindful prescribing and understanding the impact an HIV diagnosis can have on one’s mental health, including social isolation• How to address patients’ needs and establish a trusting relationship within the confines of a 15-minute clinic visit• How research is helping healthcare professionals better understand this clinical situation and discover opportunities to equalize metrics• The critical role of social workers and community organizations in patients’ overall care• Accessing federal HIV disability resources• Informed patient–provider discussion and counseling on medical decision-making regarding ART• How healthcare professionals can move toward clinical practice that leaves no one behindPresenter:Babafemi Taiwo, MBBSGene Stollerman Professor of MedicineChiefDivision of Infectious DiseasesNorthwestern University Feinberg School of MedicineChicago, IllinoisVincent CrisostomoDirectorAging ServicesSan Francisco AIDS FoundationSan Francisco, CaliforniaLink to full program:https://bit.ly/3TqVnl1 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Kevin Astle, PharmD, BCPS, BCACP, AAHIVP, CDCES, discusses data and recommendations for providing HIV prevention options as a strategy to support PrEP persistence and engagement, including: Postexposure prophylaxis (PEP) recommendations and the data for PEP-in-PocketOffering PrEP to everyone who receives PEPCurrently recommended PrEP options and the safety and adverse event considerations with each optionMonitoring recommendations for the different PrEP optionsThe importance of proactively addressing PrEP safety concerns that could lead to PrEP discontinuationFacultyKevin Astle, PharmD, BCPS, BCACP, AAHIVP, CDCESAssistant ProfessorPharmacotherapeutics and Clinical ResearchUniversity of South Florida Taneja College of MedicineTampa, FloridaFollow along with the slides:bit.ly/48cULUNLink to full program:bit.ly/3ZlICsL Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

During the 2023 American Association for the Study of Liver Diseases conference, exciting and important results from many primary biliary cholangitis (PBC) clinical trials were reported, including 3 late-breaking studies on the PPAR-δ agonist seladelpar, the dual PPAR agonist elafibranor, and the combination of the FXR agonist obeticholic acid and a fibrate.In this episode, Kris V. Kowdley MD, FAASLD, FACP, FACG, discusses topline results from several of these studies and more, including: A combination of 3 studies—HEROES, COBALT, and COBALT EC—that evaluated the real-world effectiveness and safety of second-line therapy in PBC where OCA was added to the treatment regimen of people with PBC with an incomplete response to ursodeoxycholic acid Lessons learned from a long-term outcomes study of people with PBCResults from 2 phase II studies of obeticholic acid plus bezafibrate in people with PBC who did not respond to or were intolerant of ursodeoxycholic acidPresenter:Kris V. Kowdley MD, FAASLD, FACP, FACGProfessor, Elson S. Floyd College of MedicineWashington State UniversityDirector, Liver Institute NorthwestSeattle, Washington Link to reviews of other PBC studies from AASLD 2023: https://bit.ly/3RvXXEI Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Dr Tavell Kindall and Jona Tanguay discuss actionable strategies for advanced practice providers to increase the frequency at which PrEP is offered and initiated in primary care settings. Topics covered include:Available training resources on how to offer PrEP in primary careAffordable, accessible PrEP options, including patient assistance programsUsing electronic health records to identify candidates for PrEPOpportunities to offer PrEP during appointments regarding birth control, STIs, or any other sexual health concernsHow to offer 3-site STI testing at your facilityWrapping PrEP into primary careIncorporating navigators or care coordinators to reduce logistical barriers and reach underserved populationsRapid testing, mobile testing, and Tele-PrEP as ways to facilitate PrEP initiation and simplify routine PrEP visitsHealthcare professionals’ personal biases as a potential barrier to PrEPUsing ICD-10 codes for HIV PrEP as a way to further destigmatize PrEP and simplify billingFaculty:Tavell L. Kindall, PhD, DNP, ARNP, FNP-BC, AACRN, AAHIVS, FAANPDirector, HIV Prevention and TreatmentSt. Thomas Community Health CenterNew Orleans, LouisianaJona Tanguay, MMSc, PA-C, AAHIVSMedical Program Lead - Substance Use Disorders at Whitman-Walker HealthAssociate Medical Director - Transgender Health at Amida CarePresident-Elect at GLMA: Health Professionals Advancing LGBTQ+ EqualityClinical Instructor at Yale School of MedicineFounder at ChemsexHarmReduction.orgWashington, DCContent is supported by independent educational grants from Gilead Sciences, Inc. and ViiV Healthcare.Link to full program: https://bit.ly/3PZGYdR Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this third of 3 episodes, global HIV experts and advocates discuss the current status of HIV cure research, including key concepts to understand and communicate when counselling patients, colleagues, and the broader community on HIV cure: Latest understanding of the viral reservoirNew insights and questions on the best timing for cure interventionsCurrent investigational strategies showing promiseEthical considerations related to participant education, representation in clinical trials, and planning for broad global accessFaculty: Katharine J. Bar, MDAssociate Professor of MedicineDirector, Penn CFAR Virus and Reservoirs CoreUniversity of PennsylvaniaPhiladelphia, PennsylvaniaJennifer Blanchette, PhDIndependent ContractorClinical Care OptionsColorado, United StatesKrista L. Dong, MDClinical Director, FRESH CohortAssistant Professor of MedicineMassachusetts General HospitalHarvard Medical SchoolBoston, MassachusettsKarine Dubé, DrPH, MPhilAssociate ProfessorUCSD School of MedicineDivision of Infectious Diseases and Global Public HealthSan Diego, CaliforniaRichard JefferysBasic Science, Vaccines & Cure Project DirectorTreatment Action GroupNew York, New YorkSharon R. Lewin, AO, FRACP, PhD, FAA, FAHMSDirectorDoherty InstituteMelbourne Laureate Professor and HeadDepartment of Infectious DiseasesThe University of MelbourneConsultant PhysicianVictorian Infectious Diseases ServiceRoyal Melbourne HospitalConsultant Physician and Adjunct Professor Department of Infectious DiseasesAlfred Hospital and Monash UniversityMelbourne, AustraliaAngelina Namiba Founder Member4M Network of Mentor MothersLondon, United KingdomLink to full program:https://bit.ly/3QFwv7n Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast, Julie Ann Justo, PharmD, MS, FIDSA, BCPS, discusses treatment of carbapenem-resistant Enterobacterales (CRE) infections, including:Burden of CRE infections in the United StatesMechanisms of resistanceChanging epidemiologyUse of rapid diagnostic testsIDSA guidance recommendations, including supporting dataApproach to designing treatment regimens, including weighing patient- and infection-related factorsFaculty:Julie Ann Justo, PharmD, MS, FIDSA, BCPSClinical Pharmacist Lead – Infectious DiseasesInpatient PharmacyDartmouth Hitchcock Medical CenterLebanon, New HampshireLink to full program: https://bit.ly/41a8Mj0Link to accompanying ClinicalThought commentary:https://bit.ly/4865T57Link to downloadable infographic: https://bit.ly/3t7NpT2 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Errol L. Fields, MD, PhD, MPH, and Armonté Butler, MPH, a pre-exposure prophylaxis (PrEP) advocate, discuss strategies for overcoming barriers to uptake of PrEP for HIV in adolescents and young adults, based on the unique needs of this patient population. Topics covered include:Methods for building trust between patients and providersWays to practice shared decision-making and how this process hinges on respecting patients’ autonomy and personhoodHow to empower young people to ask for the assistance they needHow to navigate consent and confidentiality issuesInformation about payment optionsStrategies to improve adherence for youthThe best ways to provide support and flexibility throughout this process to promote persistence on PrEP Faculty:Errol L. Fields, MD, PhD, MPHAssociate Professor of PediatricsDivision of Adolescent/Young Adult MedicineDepartment of PediatricsJohns Hopkins School of MedicineBaltimore, MarylandArmonté Butler, MPHAssociate Director, LGBTQ Health & RightsAdvocates for YouthWashington, DCContent is supported by independent educational grants from Gilead Sciences, Inc. and ViiV Healthcare.Link to full program: https://bit.ly/3PZGYdR Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

During the 2023 American Association of the Study of Liver Diseases (AASLD) conference, exciting and important results from many primary biliary cholangitis (PBC) clinical trials were reported, including 3 late-breaking studies on the PPAR-delta agonist seladelpar, the dual PPAR agonist elafibranor, and the combination of the FXR agonist obeticholic acid and a fibrate.In this episode, Stuart C. Gordon, MD, FAASLD, discusses topline results from one of these late-breaking studies and more, including: A phase III study of an investigational PPAR-delta agonist (seladelpar) in people with PBC who had failed to respond to ursodeoxycholic acidA study that explored racial differences as they relate to the presentation and diagnosis of PBCPresenter: Stuart C. Gordon, MD, FAASLDDirector of HepatologyHenry Ford Health SystemProfessor of MedicineWayne State University School of MedicineDetroit, MichiganLink to commentary:https://bit.ly/3GzRMt2Link to reviews of other PBC studies from AASLD 2023:https://bit.ly/3RvXXEI Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

During the 2023 American Association of the Study of Liver Diseases (AASLD) conference, exciting and important results from many primary biliary cholangitis (PBC) clinical trials were reported, including 3 late-breaking studies on the PPAR-delta agonist seladelpar, the dual PPAR agonist elafibranor, and the combination of the FXR agonist obeticholic acid and a fibrate.In this episode, Marlyn J. Mayo, MD, discusses topline results from several of these studies and more, including: A phase III study of an investigational dual PPAR α/δ agonist (elafibranor) in people with PBC who did not respond to or were intolerant of ursodeoxycholic acid (UDCA)A study that evaluated the effectiveness and safety of second-line therapy in PBC where obeticholic acid with or without a fibrate was added to the treatment regimen of people with PBC with an incomplete response to UDCAA retrospective review of the rates of hyperlipidemia, atherosclerosis, and/or hepatic steatosis in patients with PBCPresenter: Marlyn J. Mayo, MDProfessor of Internal MedicineDivision of Digestive & Liver DiseasesUT Southwestern Medical CenterDallas, TexasLink to commentary:https://bit.ly/47PmGdcLink to reviews of other PBC studies from AASLD 2023: https://bit.ly/3RvXXEI Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.